Pregabalin Zentiva 75 mg hard capsules EFG
Spain
Table of Contents
Patient Information Leaflet
Introduction
Package leaflet: Information for the user
Pregabalina Zentiva 25 mg hard capsules EFG
Pregabalina Zentiva 50 mg hard capsules EFG
Pregabalina Zentiva 75 mg hard capsules EFG
Pregabalina Zentiva 100 mg hard capsules EFG
Pregabalina Zentiva 150 mg hard capsules EFG
Pregabalina Zentiva 200 mg hard capsules EFG
Pregabalina Zentiva 225 mg hard capsules EFG
Pregabalina Zentiva 300 mg hard capsules EFG
pregabalin
Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, consult your doctor or pharmacist.
- This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, as it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Leaflet contents
- What Pregabalina Zentiva is and what it is used for
- What you need to know before taking Pregabalina Zentiva
- How to take Pregabalina Zentiva
- Possible side effects
- How to store Pregabalina Zentiva
- Contents of the pack and other information
1. What is Pregabalin Zentiva and what is it used for
Pregabalin Zentiva belongs to a group of medicines used to treat epilepsy, neuropathic pain, and generalized anxiety disorder (GAD) in adults.
Peripheral and central neuropathic pain
Pregabalin Zentiva is used to treat chronic pain caused by nerve damage. Various diseases can cause peripheral neuropathic pain, such as diabetes or shingles (herpes). The sensation of pain may be described as warmth, burning, throbbing, shooting, stabbing, sharp pain, spasms, continuous pain, tingling, numbness, or prickling sensations. Peripheral and central neuropathic pain may also be associated with mood changes, sleep disturbances, fatigue, and may affect physical and social activity and overall quality of life.
Epilepsy
Pregabalin Zentiva is used to treat certain types of epilepsy (partial seizures with or without secondary generalization) in adults. Your doctor will prescribe Pregabalin Zentiva when your current treatment does not adequately control your condition. You should take Pregabalin Zentiva as an add-on to your current therapy. Pregabalin Zentiva must not be used as monotherapy, but always in combination with other antiepileptic treatments.
Generalized anxiety disorder
Pregabalin Zentiva is used to treat generalized anxiety disorder (GAD). Symptoms of GAD include excessive and prolonged anxiety and worry that are difficult to control. GAD may also cause restlessness or a feeling of being keyed-up or on edge, easy fatigue, difficulty concentrating or mind going blank, irritability, muscle tension, or sleep disturbance. This is different from the stress and pressures of everyday life.
2. What you need to know before starting Pregabalin Zentiva
Do not take Pregabalin Zentiva
- if you are allergic to pregabalin or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting Pregabalin Zentiva.
- Some patients treated with pregabalin have reported symptoms indicating an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as development of a widespread skin rash. If you experience any of these symptoms, you must seek immediate medical attention.
- Pregabalin has been associated with dizziness and somnolence, which could increase the risk of accidental injuries (falls) in elderly patients. Therefore, you should exercise caution until you become familiar with the effects of the medicine.
- Pregabalin may cause blurred vision, vision loss, or other changes in eyesight, many of which are transient. If you experience any changes in your vision, you must inform your doctor immediately.
- Diabetic patients who gain weight while taking pregabalin may require adjustments in their diabetes medications.
- Certain adverse effects, such as somnolence, may be more frequent in patients with spinal cord injury, as they may be taking other medications for treatment (e.g., for pain or spasticity—tight or rigid muscles) that have adverse effects similar to those of pregabalin, potentially increasing the intensity of these effects when taken together.
- Cases of heart failure have been reported in some patients treated with pregabalin. Most of these patients were elderly and had cardiovascular diseases. Before using this medicine, you must inform your doctor if you have a history of heart disease.
- Cases of renal failure have been reported in some patients treated with pregabalin. If during treatment with Pregabalin Zentiva you notice a decrease in your ability to urinate, inform your doctor, as discontinuation of treatment may improve this condition.
- A small number of people taking antiepileptic medicines such as pregabalin have had thoughts of harming themselves or of suicide. If at any time you experience such thoughts, contact your doctor as soon as possible.
- When pregabalin is taken together with other medicines that may cause constipation (such as certain types of pain medications), gastrointestinal problems (e.g., constipation, intestinal blockage, or intestinal paralysis) may occur. Inform your doctor if you develop constipation, especially if you are prone to this condition.
- Before taking this medicine, you must inform your doctor if you have a history of alcoholism or of drug abuse, dependence, or addiction. Do not take a higher dose than the one prescribed to you.
- Cases of seizures during treatment with pregabalin or shortly after discontinuation have been reported. If you experience seizures, contact your doctor immediately.
- Cases of reduced brain function (encephalopathy) have been reported in some patients taking pregabalin who also had other medical conditions. Inform your doctor if you have a history of any serious illness, including liver or kidney disease.
Children and adolescents
The safety and efficacy of pregabalin have not been established in children and adolescents (under 18 years of age); therefore, pregabalin should not be used in this age group.
Using Pregabalin Zentiva with other medicines
Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Pregabalin Zentiva and certain medicines can affect each other (interactions). When pregabalin is used together with certain medicines that have sedative effects (including opioids), these effects may be enhanced, potentially leading to respiratory failure, coma, and death. The degree of dizziness, somnolence, and reduced concentration may increase if pregabalin is taken together with other medicines containing:
- oxycodone (used as an analgesic)
- lorazepam (used to treat anxiety)
- alcohol.
Pregabalin Zentiva can be taken with oral contraceptives.
Taking Pregabalin Zentiva with food, drinks, and alcohol
Pregabalin Zentiva capsules can be taken with or without food.
It is advised not to drink alcohol during treatment with Pregabalin Zentiva.
Pregnancy and breastfeeding
Do not take Pregabalin Zentiva during pregnancy or breastfeeding unless your doctor has instructed you to do so. An effective method of contraception should be used in women of childbearing age. If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
Pregabalin may cause dizziness, somnolence, and reduced concentration. You should not drive, operate heavy machinery, or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform such tasks.
Pregabalin Zentiva contains lactose monohydrate
If your doctor has diagnosed you with an intolerance to certain sugars, consult with him before taking this medicine.
3. How to take Pregabaline Zentiva
Follow exactly the instructions given by your doctor for taking this medicine.
If in doubt, consult your doctor or pharmacist again.
Your doctor will determine the appropriate dose for you.
Pregabaline Zentiva is for oral use only.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder
Take the number of hard capsules your doctor has indicated.
The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg daily.
Your doctor will instruct you to take Pregabaline Zentiva two or three times a day. If twice daily, take Pregabaline Zentiva once in the morning and once at night, approximately at the same time each day. If three times daily, take Pregabaline Zentiva in the morning, at midday, and at night, approximately at the same time each day.
If you feel that the effect of Pregabaline Zentiva is too strong or too weak, inform your doctor or pharmacist.
If you are an elderly patient (over 65 years of age), you should take Pregabaline Zentiva as usual, unless you have kidney problems.
Your doctor may prescribe a different dosing regimen and/or different doses if you have kidney problems.
Swallow the capsule whole with water.
Continue taking Pregabaline Zentiva until your doctor tells you to stop.
If you take more Pregabaline Zentiva than you should
Call your doctor or go to the nearest emergency department immediately. Take the Pregabaline Zentiva hard capsule pack with you. As a result of taking more Pregabaline Zentiva than you should, you may feel drowsy, confused, agitated, or restless. Seizures have also been reported.
If you forget to take Pregabaline Zentiva
It is important to take Pregabaline Zentiva capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember, unless it is nearly time for your next dose. In that case, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed dose.
If you stop taking Pregabaline Zentiva
Do not stop taking Pregabaline Zentiva unless your doctor tells you to. If you are going to stop treatment, it should be done gradually over a minimum of one week.
After stopping long-term or short-term treatment with Pregabaline Zentiva, you should be aware that you may experience certain adverse effects. These include sleep problems, headache, nausea, feeling of anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, pain, sweating, and dizziness. These symptoms may occur more frequently or severely if you have been taking pregabalin for a longer period of time.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.
Very common: may affect more than 1 in 10 people
- Dizziness, somnolence, headache.
Common: may affect up to 1 in 10 people
- Increased appetite.
- Feeling of euphoria, confusion, disorientation, decreased sexual appetite, irritability.
- Attention disturbance, clumsiness, memory impairment, memory loss, tremors, difficulty speaking, tingling sensation, numbness, sedation, lethargy, insomnia, fatigue, abnormal sensation.
- Blurred vision, double vision.
- Dizziness, balance problems, falls.
- Dry mouth, constipation, vomiting, flatulence, diarrhea, nausea, bloated abdomen.
- Difficulty in erection.
- Swelling of the body including limbs.
- Feeling of drunkenness, disturbances in gait.
- Weight gain.
- Muscle cramps, joint pain, back pain, limb pain.
- Sore throat.
Uncommon: may affect up to 1 in 100 people
- Loss of appetite, weight loss, low blood sugar levels, high blood sugar levels.
- Altered self-perception, restlessness, depression, agitation, mood changes, difficulty finding words, hallucinations, strange dreams, panic attacks, apathy, aggressiveness, elevated mood, mental deterioration, difficulty thinking, increased sexual appetite, problems in sexual relations including inability to reach climax, delayed ejaculation.
- Visual disturbances, unusual eye movements, vision changes including tunnel vision, flashes of light, spasmodic movements, diminished reflexes, hyperactivity, dizziness upon standing, sensitive skin, loss of taste, burning sensation, movement-related tremor, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, general malaise.
- Dry eyes, eye swelling, eye pain, tired eyes, watery eyes, eye irritation.
- Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heart rhythm, heart failure.
- Flushing, hot flushes.
- Difficulty breathing, dry nose, nasal congestion.
- Increased saliva production, burning sensation, numbness around the mouth.
- Sweating, rash, chills, fever.
- Muscle spasms, joint swelling, muscle stiffness, pain including muscle pain, neck pain.
- Breast pain.
- Difficulty or pain when urinating, inability to control urine.
- Weakness, thirst, chest tightness.
- Changes in blood and liver test results (elevated blood creatine phosphokinase, elevated alanine aminotransferase, elevated aspartate aminotransferase, decreased platelet count, neutropenia, increased blood creatinine, low blood potassium).
- Hypersensitivity, facial swelling, itching, urticaria, runny nose, nosebleeds, cough, snoring.
- Painful menstrual periods.
- Cold sensation in hands and feet.
Rare: may affect up to 1 in 1,000 people
-
Altered sense of smell, flickering vision, altered depth perception, visual glare, vision loss.
-
Dilated pupils, strabismus.
-
Cold sweat, throat tightness, tongue swelling.
-
Pancreatitis.
-
Difficulty swallowing.
-
Slow or reduced body movement.
-
Difficulty writing properly.
-
Increased fluid in the abdominal area.
-
Fluid in the lungs.
-
Seizures.
-
Changes in the electrocardiogram (ECG) corresponding to heart rhythm disturbances.
-
Muscle damage.
-
Milk secretion, abnormal breast growth, breast enlargement in men.
-
Interruption of menstrual periods.
-
Kidney failure, reduced urine output, urine retention.
-
Decreased white blood cell count.
-
Inappropriate behavior.
-
Allergic reactions (which may include difficulty breathing, eye swelling (keratitis), and a severe skin reaction characterized by rash, blisters, skin peeling, and pain).
-
Jaundice (yellowing of the skin and eyes).
Very rare: may affect up to 1 in 10,000 people
- Liver failure.
- Hepatitis (inflammation of the liver).
If you experience swelling of the face or tongue, or if your skin becomes red, blistered, or peeling, you should seek immediate medical attention.
Certain adverse effects, such as somnolence, may be more frequent because patients with spinal cord injury may be taking other medications to treat, for example, pain or spasticity (stiff or rigid muscles), which have adverse effects similar to those of pregabalin, so the intensity of these effects may increase when taken together.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Pregabalin Zentiva
Keep this medicine out of the sight and reach of children.
Do not store above 30°C.
Do not use this medicine after the expiry date stated on the blister pack and carton after the letters “CAD/EXP”. The expiry date refers to the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Pregabaline Zentiva
The active substance is pregabalin. Each hard capsule contains 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg or 300 mg of pregabalin.
The other components are lactose monohydrate, pregelatinized corn starch, talc, titanium dioxide (E171), gelatin, shellac glaze, black iron oxide (E172).
The 50 mg capsules also contain propylene glycol, strong ammonia solution, potassium hydroxide.
The 25 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg capsules also contain polyethylene glycol.
The 75 mg, 100 mg, 200 mg, 225 mg, and 300 mg capsules also contain red iron oxide (E172) and yellow iron oxide (E172).
Appearance of Pregabalin Zentiva and contents of the pack | |
25 mg capsules | Light grey cap and light grey body; approximately 15.9 mm in length, hard gelatin capsule printed with “25”, containing an almost white powder. |
50 mg capsules | Light grey cap and light grey body; approximately 14.3 mm in length, hard gelatin capsule printed with “50”, containing an almost white powder. |
75 mg capsules | Red cap and light grey body; approximately 14.3 mm in length, hard gelatin capsule printed with “75”, containing an almost white powder. |
100 mg capsules | Red cap and red body; approximately 15.9 mm in length, hard gelatin capsule printed with “100”, containing an almost white powder. |
150 mg capsules | Light grey cap and light grey body; approximately 18.0 mm in length, hard gelatin capsule printed with “150”, containing an almost white powder. |
200 mg capsules | Light beige cap and light beige body; approximately 19.4 mm in length, hard gelatin capsule printed with “200”, containing an almost white powder. |
225 mg capsules | Light beige cap and light grey body; approximately 19.4 mm in length, hard gelatin capsule printed with “225”, containing an almost white powder. |
300 mg capsules | Red cap and light grey body; approximately 21.7 mm in length, hard gelatin capsule printed with “300”, containing an almost white powder. |
Pregabalin Zentiva 25 mg hard capsules are packaged in alu-alu (OPA/alu/PVC/alu) blisters as primary packaging.
Pregabalin Zentiva 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg hard capsules are packaged in PVC/alu blisters as primary packaging.
Pregabalin Zentiva 25 mg and 50 mg are available in pack sizes of 14, 21, 56, 84, 98 and 100 hard capsules.
Pregabalin Zentiva 75 mg, 150 mg, 225 mg and 300 mg are available in pack sizes of 14, 56, 98 and 100 hard capsules.
Pregabalin Zentiva 100 mg and 200 mg are available in pack sizes of 21, 84, 98 and 100 hard capsules.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Zentiva, k.s.
U Kabelovny 130
102 37 Prague 10
Czech Republic
Manufacturer
Zentiva, k.s.
U Kabelovny 130
102 37 Prague 10
Czech Republic
or
S.C. Zentiva, S.A.
B-dul Theodor Pallady nr.50, sector 3, Bucharest, cod 032266
Romania
For more information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
Belgium/Belgium/Belgium Zentiva, k.s. Tel/Tel: +32 280 86 420 | Lithuania Zentiva, k.s. Tel: +370 52152025 |
Bulgaria Zentiva, k.s. Tel: +359 2 805 72 08 | Luxembourg/Luxembourg Zentiva, k.s. Tel/Tel: +352 208 82330 |
Czech Republic Zentiva, k.s. Tel: +420 267 241 111 | Hungary Zentiva, k.s. Tel.: +36 165 55 722 |
Denmark Zentiva, k.s. Tlf: +45 787 68 400 | Malta Zentiva, k.s. Tel: +356 277 82 052 |
Germany Zentiva Pharma GmbH Tel: +49 (0) 800 53 53 010 | Netherlands Zentiva, k.s. Tel: +31 202 253 638 |
Estonia Zentiva, k.s. Tel: +372 52 70308 | Norway Zentiva, k.s. Tlf: +47 219 66 203 |
Greece Zentiva, k.s. Tel: +30 211 198 7510 | Austria Zentiva, k.s. Tel: +43 720 778 877 |
Spain Zentiva, k.s. Tel: +34 931 815 250 | Poland Zentiva Polska Sp. z o.o. Tel: +48 22 375 92 00 |
France Zentiva France Tél: +33 (0) 800 089 219 | Portugal Zentiva Portugal, Lda Tel: +351210601360 |
Croatia Zentiva, k.s. Tel: +385 155 17 772 | Romania ZENTIVA S.A. Tel: +40 021.304.7597 |
Ireland Zentiva, k.s. Tel: +353 766 803 944 | Slovenia Zentiva, k.s. Tel: +386 360 00 408 |
Iceland Zentiva, k.s. Tel: +354 539 0650 | Slovakia Zentiva, a.s. Tel: +421 2 3918 3010 |
Italy Zentiva Italia S.r.l. Tel: +39-02-38598801 | Finland/Finland Zentiva, k.s. Tel/Tel: +358 942 598 648 |
Cyprus Zentiva, k.s. Tel: +357 240 30 144 | Sweden Zentiva, k.s. Tel: +46 840 838 822 |
Latvia Zentiva, k.s. Tel: +371 67893939 | United Kingdom Zentiva Pharma UK Limited Tel: +44 (0) 845 372 7101 |
Date of the most recent review of this leaflet:
Other sources of information
Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.